EA201590914A1 - TGFβ-ВЫДЕЛЕННЫЕ ПОЛИПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ - Google Patents

TGFβ-ВЫДЕЛЕННЫЕ ПОЛИПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA201590914A1
EA201590914A1 EA201590914A EA201590914A EA201590914A1 EA 201590914 A1 EA201590914 A1 EA 201590914A1 EA 201590914 A EA201590914 A EA 201590914A EA 201590914 A EA201590914 A EA 201590914A EA 201590914 A1 EA201590914 A1 EA 201590914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tgfβ
present
ability
diseases
alk5
Prior art date
Application number
EA201590914A
Other languages
English (en)
Other versions
EA031990B1 (ru
Inventor
Анхель де Хесус Корриа Осорио
Калет Леон Монсон
Таня Карменате Портилла
Амаури ПУПО МЕРИНЬО
Саумель Перес Родригес
Original Assignee
Сентро Де Инмунологиа Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентро Де Инмунологиа Молекулар filed Critical Сентро Де Инмунологиа Молекулар
Publication of EA201590914A1 publication Critical patent/EA201590914A1/ru
Publication of EA031990B1 publication Critical patent/EA031990B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к области биотехнологии и, в частности, к мутированным полипептидам молекулы TGFβ, первичная последовательность которой обладает высокой гомологией с последовательностью TGFβ человека. Указанные мутеины утрачивают способность взаимодействовать с ALK5, но сохраняют способность взаимодействовать с другими рецепторами, входящими в комплекс рецепторов (TβRII и TβRIII). Мутеины по настоящему изобретению обладают способностью оказывать антагонистическое воздействие на передачу сигналов всех природных вариантов лигандов TGFβ, зависящую от рекрутинга ALK5 в комплекс рецепторов, и характеризуются значительным иммуномодулирующим действием. Настоящее изобретение также относится к фармацевтическим композициям, включающим в качестве активного компонента полипептиды или гибридные белки по настоящему изобретению, и к применению указанных композиций для оказания модулирующего воздействия на иммунную систему в случае таких заболеваний, как рак, заболевания, сопровождаемые фиброзом, и хронические инфекционные заболевания.
EA201590914A 2012-11-09 2013-10-30 МУТАНТНЫЕ ПОЛИПЕПТИДЫ TGFβ И ИХ ПРИМЕНЕНИЕ EA031990B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (2)

Publication Number Publication Date
EA201590914A1 true EA201590914A1 (ru) 2015-09-30
EA031990B1 EA031990B1 (ru) 2019-03-29

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590914A EA031990B1 (ru) 2012-11-09 2013-10-30 МУТАНТНЫЕ ПОЛИПЕПТИДЫ TGFβ И ИХ ПРИМЕНЕНИЕ

Country Status (28)

Country Link
US (1) US9701730B2 (ru)
EP (1) EP2918284B1 (ru)
JP (2) JP6298823B2 (ru)
KR (1) KR102093494B1 (ru)
CN (1) CN104902916B (ru)
AR (1) AR093391A1 (ru)
AU (1) AU2013344022B2 (ru)
BR (1) BR112015010145B1 (ru)
CA (1) CA2887455C (ru)
CL (1) CL2015001252A1 (ru)
CO (1) CO7400865A2 (ru)
CU (1) CU24181B1 (ru)
EA (1) EA031990B1 (ru)
ES (1) ES2857176T3 (ru)
HK (1) HK1213781A1 (ru)
IL (1) IL238621B (ru)
JO (1) JO3502B1 (ru)
MX (1) MX366060B (ru)
MY (1) MY173078A (ru)
NZ (1) NZ707850A (ru)
PE (1) PE20150890A1 (ru)
PH (1) PH12015500807A1 (ru)
SG (1) SG11201502980VA (ru)
TN (1) TN2015000129A1 (ru)
TW (1) TWI615404B (ru)
UA (1) UA115678C2 (ru)
WO (1) WO2014071894A1 (ru)
ZA (1) ZA201504462B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541409A4 (en) * 2016-11-18 2020-06-17 University of Pittsburgh - of The Commonwealth System of Higher Education MANIPULATED TGF-BETA MONOMERS AND THEIR USE FOR INHIBITING TGF-BETA SIGNALING
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065948A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
CA2344277A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
JP2008509888A (ja) * 2004-06-30 2008-04-03 モレキュラー ロジックス，インコーポレイテッド 上皮成長因子受容体アンタゴニストおよび使用方法
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CN101365712A (zh) * 2005-01-11 2009-02-11 莫勒丘尔洛吉克斯有限公司 Pan-HER拮抗剂及其使用方法
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂

Also Published As

Publication number Publication date
CN104902916B (zh) 2018-04-13
PE20150890A1 (es) 2015-06-10
KR20150083848A (ko) 2015-07-20
BR112015010145B1 (pt) 2022-06-07
MX366060B (es) 2019-06-26
EP2918284B1 (en) 2021-02-17
EA031990B1 (ru) 2019-03-29
AU2013344022B2 (en) 2016-12-15
WO2014071894A1 (es) 2014-05-15
BR112015010145A2 (ru) 2017-08-22
MX2015005875A (es) 2015-09-10
IL238621A0 (en) 2015-06-30
JO3502B1 (ar) 2020-07-05
KR102093494B1 (ko) 2020-03-26
TWI615404B (zh) 2018-02-21
US9701730B2 (en) 2017-07-11
HK1213781A1 (zh) 2016-07-15
ES2857176T3 (es) 2021-09-28
JP2018111703A (ja) 2018-07-19
CO7400865A2 (es) 2015-09-30
CA2887455A1 (en) 2014-05-15
UA115678C2 (uk) 2017-12-11
JP6298823B2 (ja) 2018-03-20
AU2013344022A1 (en) 2015-05-28
JP6608473B2 (ja) 2019-11-20
CU20120158A7 (es) 2014-06-27
MY173078A (en) 2019-12-25
CN104902916A (zh) 2015-09-09
TN2015000129A1 (en) 2016-10-03
US20150284441A1 (en) 2015-10-08
ZA201504462B (en) 2018-11-28
CL2015001252A1 (es) 2015-07-17
AR093391A1 (es) 2015-06-03
NZ707850A (en) 2019-08-30
PH12015500807A1 (en) 2015-06-08
EP2918284A1 (en) 2015-09-16
TW201431875A (zh) 2014-08-16
CA2887455C (en) 2022-05-17
JP2015535000A (ja) 2015-12-07
IL238621B (en) 2019-12-31
CU24181B1 (es) 2016-04-25
SG11201502980VA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
EA201390681A1 (ru) Производные полипептиды il-2 с агонистической активностью для лечения рака и хронических инфекций
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
EA201491644A1 (ru) Фармацевтические композиции
CA2856895C (en) Anti-pd-l1 antibodies and uses thereof
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201390993A1 (ru) Антитела к cd38
UA112416C2 (uk) Антитіло до fap і способи його застосування
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
EA201491973A1 (ru) Новые соединения
PH12015502591A1 (en) Stable formulations of immunoglobulin single variable domains and uses thereof
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
MX368996B (es) Formulaciones de anticuerpos y usos de las mismas.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
UA114298C2 (uk) Пептид торк та вакцина, що його містить
EA201590914A1 (ru) TGFβ-ВЫДЕЛЕННЫЕ ПОЛИПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ
FR2974805B1 (fr) Nouveaux peptides modulateurs de la proteine trf-2 et compositions les comprenant
EP3438261A4 (en) THERAPEUTIC FOR AUTOIMMUNE DISEASE WITH AN ANTIBODY BUTTING TO HAPTOGLOBIN IN THE BLOOD FOR THE FORMATION OF A POLYVALENT IMMUNKOMPLEX AS AN ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM